Welcome to our dedicated page for Arcus Bioscience news (Ticker: RCUS), a resource for investors and traders seeking the latest updates and insights on Arcus Bioscience stock.
Arcus Biosciences, Inc. (NYSE: RCUS) generates frequent news as a clinical-stage, global biopharmaceutical company advancing investigational therapies for cancer, inflammatory diseases and autoimmune diseases. News about Arcus often centers on clinical trial updates for its lead programs, collaboration developments and corporate financing activities that support its pipeline.
Key oncology news items include data readouts and study milestones for casdatifan, a small-molecule HIF‑2α inhibitor being developed for clear cell renal cell carcinoma (ccRCC). Investors can follow announcements from the ARC‑20 Phase 1/1b study in late-line and early-line ccRCC, the global Phase 3 PEAK‑1 trial in immunotherapy-experienced metastatic ccRCC, and the eVOLVE‑RCC02 Phase 1b/3 study that combines casdatifan with volrustomig in first-line metastatic ccRCC. Updates often highlight progression-free survival, response rates, safety findings and the design of new cohorts or registrational strategies.
Arcus news also covers its broader oncology portfolio, including quemliclustat, a CD73 inhibitor in the PRISM‑1 Phase 3 trial for first-line metastatic pancreatic ductal adenocarcinoma, and the domvanalimab plus zimberelimab combinations in gastrointestinal and lung cancers. Coverage has included positive survival and response data from the Phase 2 EDGE‑Gastric study, as well as the later decision to discontinue the Phase 3 STAR‑221 and EDGE‑Gastric studies after an interim analysis showed no overall survival benefit over standard therapy.
On the inflammation and immunology side, Arcus issues updates on its emerging small-molecule programs targeting MRGPRX2, TNF, CCR6 and CD40L, and an anti‑CD89 antibody program. News may describe preclinical progress, selection of development candidates and plans to enter the clinic in indications such as atopic dermatitis, chronic spontaneous urticaria, rheumatoid arthritis, psoriasis, inflammatory bowel disease, multiple sclerosis and systemic lupus erythematosus.
Corporate and financial news for RCUS includes public equity offerings, amendments to loan facilities, participation in major healthcare and investor conferences, and guidance on cash runway. Readers can use this news page to follow how clinical data, partnership decisions with Gilead Sciences and Taiho Pharmaceutical, and capital-raising activities shape Arcus’s development priorities over time.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Arcus Biosciences, Inc. (NYSE:RCUS), a biopharmaceutical company focused on cancer treatments, announced the grant of equity awards to six new employees. The awards include options to purchase a total of 17,600 shares at an exercise price of
The company aims to develop innovative cancer therapies in collaboration with industry partners and has six investigational medicines in clinical studies targeting various biological pathways.
Arcus Biosciences, Inc. (NYSE:RCUS) announced the granting of stock options and restricted stock units to nine new employees. A total of 34,000 options at an exercise price of $17.36 per share and 15,200 restricted stock units were issued. The options were granted under the company’s 2020 Inducement Plan, which was approved in January 2020.
Arcus is focused on developing innovative therapies for cancer treatment, examining molecules targeting various biological pathways. Founded in 2015, it currently has six investigational medicines in clinical studies.
Arcus Biosciences (NYSE:RCUS) announced the grant of stock options and restricted stock units to eight new employees as part of its 2020 Inducement Plan. A total of 66,200 options were granted at an exercise price of $17.78, the closing price on March 8, 2023, along with 33,100 restricted stock units. This move aims to attract talent in the clinical-stage biopharmaceutical sector, focusing on innovative therapies for cancer treatment. Founded in 2015, Arcus is advancing six investigational drugs targeting various cancer pathways.
Arcus Biosciences (NYSE:RCUS), a clinical-stage biopharmaceutical company, announced participation in a fireside chat at the Barclays Global Healthcare Conference on March 14, 2023, at 8:30 a.m. ET in Miami Beach, Florida. The chat will be accessible via live webcast through the Investors & Media section of the Arcus website.
Founded in 2015, Arcus focuses on developing innovative therapies for cancer, including investigational drugs targeting TIGIT and PD-1. The company aims to enhance the efficacy of cancer treatment through unique biological combinations.
Arcus Biosciences reported Q4 and full-year 2022 financial results, highlighting a net loss of $67 million for Q4 and $267 million for the full year. Revenues dropped to $34 million in Q4, down from $355 million in the previous year. The firm holds $1.1 billion in cash and equivalents, sufficient to fund operations into 2026. Domvanalimab, their lead molecule, has shown promising results in ongoing Phase 3 studies, particularly in non-small cell lung cancer (NSCLC), with median progression-free survival extending to 12 months. Updates on clinical studies and further data presentations are expected throughout 2023.
Arcus Biosciences (NYSE:RCUS) has granted stock options to three new employees, totaling 7,000 shares at an exercise price of $18.66, the closing price on February 23, 2023. Additionally, restricted stock units were awarded for 3,500 shares. These grants fall under the 2020 Inducement Plan approved in January 2020 and adhere to NYSE rules. Arcus is a clinical-stage biopharmaceutical firm focused on innovative cancer therapies, developing six investigational medicines targeting various biological pathways.